Table 6.
Post‐LTX Blood Biochemistry: Median Values per Patient for Each Disease
| Serum Assay |
FIC1 Median (IQR) n |
BSEP Median (IQR) n |
P for FIC1 vs. BSEP* |
Effect/Trend (95% CI) |
|---|---|---|---|---|
| ALT (FULN) |
1.6 (1.1‐2.3) n = 16 |
0.8 (0.5‐0.9) n = 23 |
<0.0001 |
97% higher in FIC1 (30%‐190% higher) |
| AST (FULN) |
1.6 (1.1‐2.2) n = 18 |
0.9 (0.7‐1.0) n = 27 |
0.0083 |
61% higher in FIC1 (17%‐107% higher) |
| Total bilirubin (mg/dL) |
0.4 (0.3‐0.6) n = 18 |
0.9 (0.5‐1.0) n = 26 |
0.46 |
0.2 mg lower in FIC1 (0.5 mg lower to 0.3 mg higher) |
| GGT† (FULN) |
0.7 (0.3‐1.6) n = 16 |
0.3 (0.2‐0.8) n = 27 |
0.037 |
77% higher in FIC1 (4%‐274% higher) |
| Albumin‡ (FLLN) |
1.0 (0.8‐1.0) n = 18 |
1.1 (1.0‐1.2) n = 18 |
0.0052 |
17% lower in FIC1 (7%‐24% lower) |
| Total protein (FLLN) |
1.0 (1.0‐1.2) n = 17 |
1.2 (1.1‐1.2) n = 17 |
0.06 |
9% lower in FIC1 (16% lower to 0.5% higher) |
| Cholesterol (FULN) |
0.4 (0.3‐0.6) n = 8 |
0.6 (0.5‐0.7) n = 19 |
0.027 |
37% lower in FIC1 (8%‐57% lower) |
| Hemoglobin (FLLN) |
1.0 (0.9‐1.1) n = 16 |
1.1 (1.1‐1.2) n = 24 |
0.0007 |
16% lower in FIC1 (5%‐27% lower) |
| ALP (IU/L) |
292 (199‐445) n = 19 |
255 (212‐319) n = 20 |
0.43 |
14% higher in FIC1 (20% lower to 70% higher) |
| Hematocrit (FLLN) |
1.0 (1.0‐1.1) n = 11 |
1.1 (1.0‐1.3) n = 21 |
0.24 |
8% lower in FIC1 (20% lower to 6% higher) |
| Triglycerides (FULN) |
0.3 (0.3‐0.5) n = 8 |
0.3 (0.2‐1.0) n = 12 |
0.95 |
7% lower in FIC1 (58% lower to 118% higher) |
P values <0.05 are noted in bold.
n, number of patients for whom data were available. Median value per patient was used for patients for whom results of multiple tests were available. *Comparison of geometric means, factoring in time. †The apparent gene effect on GGT may be due to effects of year of LTX and age at LTX. ‡Additional analysis indicates some of the apparent gene effect may be accounted for by an effect of steroid use. Abbreviation: ALP, alkaline phosphatase.